Cresset Asset Management, LLC Cellectis S.A. Transaction History

Cresset Asset Management, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 12, 2021	SELL	$18.19 - $33.25 $225,683 - $412,532	-12,407 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$15.87 - $31.64 $35,723 - $71,221	2,251 Added 22.16%	12,407 $336,000
Q3 2020 Nov 13, 2020	BUY	$15.7 - $20.84 $159,449 - $211,651	10,156 New	10,156 $188,000

9.73M

30.9K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $101M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Cresset Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Cresset Asset Management, LLC with notifications on news.